123 related articles for article (PubMed ID: 15624481)
21. Enzyme replacement therapy in type 1 and type 3 Gaucher's disease.
Zimran A; Elstein D; Abrahamov A
Lancet; 1995 Feb; 345(8947):451-2. PubMed ID: 7853968
[No Abstract] [Full Text] [Related]
22. Gaucher disease with pulmonary involvement in a 6-year-old girl: report of resolution of radiographic abnormalities on increasing dose of imiglucerase.
Lee SY; Mak AW; Huen KF; Lam ST; Chow CB
J Pediatr; 2001 Dec; 139(6):862-4. PubMed ID: 11743514
[TBL] [Abstract][Full Text] [Related]
23. Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy.
Beutler E
Blood Cells Mol Dis; 2000 Aug; 26(4):303-6. PubMed ID: 11042031
[No Abstract] [Full Text] [Related]
24. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
Weinreb NJ; Charrow J; Andersson HC; Kaplan P; Kolodny EH; Mistry P; Pastores G; Rosenbloom BE; Scott CR; Wappner RS; Zimran A
Am J Med; 2002 Aug; 113(2):112-9. PubMed ID: 12133749
[TBL] [Abstract][Full Text] [Related]
26. Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease.
Migita M; Hamada H; Fujimura J; Watanabe A; Shimada T; Fukunaga Y
Eur J Pediatr; 2003 Jul; 162(7-8):524-525. PubMed ID: 12845529
[No Abstract] [Full Text] [Related]
27. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement.
Ciana G; Cuttini M; Bembi B
N Engl J Med; 1997 Sep; 337(10):712. PubMed ID: 9280823
[No Abstract] [Full Text] [Related]
28. Pathologic fractures may develop in Gaucher patients receiving enzyme replacement therapy.
Sidransky E; Ginns EI; Westman JA; Ehmann WC
Am J Hematol; 1994 Nov; 47(3):247-9. PubMed ID: 7942798
[No Abstract] [Full Text] [Related]
29. Effects of imilglucerase withdrawal on an adult with Gaucher disease.
Schwartz IV; Karam S; Ashton-Prolla P; Michelin K; Coelho J; Pires RF; Pereira ML; Giugliani R
Br J Haematol; 2001 Jun; 113(4):1089. PubMed ID: 11442517
[No Abstract] [Full Text] [Related]
30. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease.
Cohen IJ; Katz K; Kornreich L; Horev G; Frish A; Zaizov R
Blood Cells Mol Dis; 1998 Sep; 24(3):296-302. PubMed ID: 10087987
[TBL] [Abstract][Full Text] [Related]
31. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
Camou F; Viallard JF
Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
[No Abstract] [Full Text] [Related]
32. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease.
Czartoryska B; Tylki-Szymańska A; Lugowska A
Clin Biochem; 2000 Mar; 33(2):147-9. PubMed ID: 10751594
[No Abstract] [Full Text] [Related]
33. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
Corso A; Varettoni M; Zappasodi P; Klersy C; Mangiacavalli S; Pica G; Lazzarino M
Leukemia; 2007 Jul; 21(7):1545-8. PubMed ID: 17410188
[TBL] [Abstract][Full Text] [Related]
34. Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate).
Ostlere L; Warner T; Meunier PJ; Hulme P; Hesp R; Watts RW; Reeve J
Q J Med; 1991 Jun; 79(290):503-15. PubMed ID: 1946931
[TBL] [Abstract][Full Text] [Related]
35. Osteonecrosis in a patient with Gaucher's disease treated with enzyme replacement.
Lebel E; Elstein D; Hain D; Hadas-Halpern I; Zimran A; Itzchaki M
Isr Med Assoc J; 2003 Aug; 5(8):595-6. PubMed ID: 12929302
[No Abstract] [Full Text] [Related]
36. [Financing of enzyme treatment in Gaucher disease].
Wisløff F
Tidsskr Nor Laegeforen; 2003 Feb; 123(3):364. PubMed ID: 12640908
[No Abstract] [Full Text] [Related]
37. Gaucher disease: resetting the clinical and scientific agenda.
Mistry PK; Weinreb NJ; Brady RO; Grabowski GA
Am J Hematol; 2009 Apr; 84(4):205-7. PubMed ID: 19296473
[No Abstract] [Full Text] [Related]
38. Enzyme therapy for Gaucher disease: the first 5 years.
Grabowski GA; Leslie N; Wenstrup R
Blood Rev; 1998 Jun; 12(2):115-33. PubMed ID: 9661800
[TBL] [Abstract][Full Text] [Related]
39. Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report.
Holubar J; Bres V; Costes-Martineau V; Pers YM
Blood Cells Mol Dis; 2018 Feb; 68():112-114. PubMed ID: 28559130
[No Abstract] [Full Text] [Related]
40. Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3.
Bembi B; Agosti E; Boehm P; Nassimbeni G; Zanatta M; Vidoni L
Acta Paediatr; 1994 Jan; 83(1):122-4. PubMed ID: 8193463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
